Aphios Corporation, a clinical-stage biotechnology company, is developing enhanced therapeutics for chronic, debilitating diseases and improving quality of life. Aphios is leading the way in developing green enabling technology platforms for improving drug discovery and manufacturing, nanotechnology drug delivery, viral vaccines, and virus-free human plasma and biologics.
Based on these platforms, Aphios is developing enhanced therapeutics for the treatment of certain cancers and supportive care, HIV, diabetes and Alzheimer’s disease. Also based on our green enabling technology platforms, we are developing, manufacturing and distributing quality-of-life (QOL) medicines for health maintenance and disease prevention through Aphios’ Health & Wellness Center.
Quality of Life (QOL) Medicines
Dietary Supplements that Lie Between Foods and Drugs for Health Maintenance and Wellness
Natural therapeutic drugs span the spectrum from highly regulated and costly drugs for sick people to lightly regulated foods for both well and sick people. Indeed, foods may be considered high-volume, low-concentration therapeutics while drugs may be considered low-volume, high-concentration foods. In between these two extremes of concentration, quantity, regulation and cost lie Aphios’ quality of life medicines (QOL) that are dietary supplements for health maintenance and wellness.
Alternative medicines are used by 38% of American adults and nearly 12% of children, according to a large national survey done in 2007 that was released in December 2008 by the National Center for Complementary and Alternative Medicine (NCCAM), National Institutes of Health (NIH). Natural products were the most popular alternative treatment used, accounting for 18% of the alternative medicines marketplace in 2007.
Aphios QOL medicines are well-characterized in terms of in vitro bioactivity and related chemistry, and they are based on human clinical evidence and/or well-documented historical use in humans.
The active botanical ingredients (ABIs) are manufactured from organically grown and wild-crafted biomass utilizing environmentally friendly and supercritical fluid technologies to produce concentrated ABIs that are truly “natural.” Our ABIs are further tested and certified to be free of residual organic solvents, pesticides, herbicides and heavy metals.
The concentrated product ABIs are then standardized, formulated and encapsulated in liquid-filled softgel or cellulosic-based hard-gel caps with a nitrogen head (e.g., Licaps®, Vegicaps®) by Capsugel, Inc. and other qualified CMOs to maximize stability and with GRAS (generally regarded as safe) excipients to enhance bioavailability.
Aphios QOL medicines are manufactured under current Good Manufacturing Practices (cGMP) guidelines of the US Food & Drug Administration (FDA), and provided to customers under the auspices of the Dietary Supplement Health and Education Act (DSHEA) of 1994.
Aphios’ QOL medicines have not been evaluated by the FDA. Aphios’ QOL medicines are not intended to diagnose, treat, cure or prevent a disease.